Aspirin's Dose and Duration of Use
Higher daily doses of aspirin increase bleeding risk, particularly gastrointestinal bleeding. Low-dose aspirin (81 mg) carries lower risk than higher therapeutic doses (325 mg or more), but risk rises with long-term use, even at low doses, as it inhibits platelet function cumulatively over time.
Concomitant Medications
Combining aspirin with other antiplatelets (clopidogrel, prasugrel) or anticoagulants (warfarin, apixaban, rivaroxaban) substantially elevates bleeding risk through additive effects on clotting. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen amplify gastrointestinal bleeding when taken with aspirin. Selective serotonin reuptake inhibitors (SSRIs) such as sertraline increase risk by impairing platelet serotonin uptake.
Patient Age and Health Conditions
Adults over 75 face higher bleeding rates due to reduced physiological reserves and higher prevalence of comorbidities. Conditions like peptic ulcer disease, Helicobacter pylori infection, chronic kidney disease, liver cirrhosis, or prior bleeding history multiply risk. Uncontrolled hypertension (>140/90 mmHg) promotes hemorrhagic stroke risk with aspirin.
Lifestyle and Behavioral Factors
Alcohol consumption, especially heavy or binge drinking, heightens gastrointestinal bleeding. Smoking may offer minor gastroprotection but increases overall cardiovascular risks that interact with aspirin's profile. Poor diet low in fruits/vegetables reduces protective factors against mucosal damage.
Strategies to Mitigate Risk
Proton pump inhibitors (PPIs) like omeprazole reduce upper GI bleeding by 70-90% in high-risk patients on aspirin. Enteric-coated formulations offer limited protection compared to plain aspirin. Testing for H. pylori and eradicating it lowers risk in susceptible individuals. Regular monitoring of kidney function and blood pressure helps tailor use.
[1] DrugPatentWatch.com - Aspirin patents and generics
[2] Lanas A, et al. (2011). "A national study of the gastrointestinal bleeding rates of aspirin vs. other nonsteroidal anti-inflammatory drugs." Clinical Gastroenterology and Hepatology.
[3] Bhatt DL, et al. (2010). "Clopidogrel with or without omeprazole in coronary artery disease." New England Journal of Medicine.
[4] Scally B, et al. (2018). "Effect of PPI on aspirin-induced gastric mucosal injury." Annals of Internal Medicine.